CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Case report: a critically ill patient with aggressive NK-cell leukemia receiving emergency chemotherapy in the ICU.
Case report: a critically ill patient with aggressive NK-cell leukemia receiving emergency chemotherapy in the ICU.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
侵袭性NK细胞白血病(ANKL)是一种罕见的成熟NK细胞肿瘤,常与EBV感染相关。我们报告一例47岁男性患者,因反复发热、黄疸和呼吸困难入院,被诊断为ANKL并伴多器官功能衰竭。转入ICU后,他接受了依托泊苷、培门冬酶和吉西他滨的紧急化疗,并结合DPMAS、LPE和CVVHD等器官支持治疗。随后,患者病情稳定并出院。然而,在第二个化疗周期后,他因精神状态改变再次入院。由于经济限制,家属决定不再继续治疗,患者最终死亡。总体而言,本病例强调了多学科协作对于管理危重ANKL患者的关键重要性。仔细评估化疗相关风险,结合在ICU中及时实施紧急化疗和全面的多器官支持,可能为患者提供生存机会。
Aggressive NK-cell leukemia (ANKL) is a scarce mature NK-cell neoplasm frequently associated with Epstein-Barr virus (EBV) infection.
We report the case of a 47-year-old male patient who was admitted to the hospital due to recurrent fever, jaundice, and dyspnea, and was diagnosed with ANKL accompanied by multi-organ failure. Upon transfer to the intensive care unit (ICU), he received emergency chemotherapy consisting of etoposide, pegaspargase, and gemcitabine, in conjunction with organ support therapies including DPMAS, LPE, and CVVHD. Subsequently, the patient s condition stabilized, and he was discharged.
However, following the second cycle of chemotherapy, he was readmitted due to altered mental status. Due to financial constraints, the family decided not to pursue further treatment, leading to the patient s eventual demise.
Overall, this case highlights the critical importance of multidisciplinary collaboration for managing critically ill ANKL patients. Careful evaluation of the risks associated with chemotherapy, combined with timely administration of emergency chemotherapy in the ICU and comprehensive multi-organ support, can potentially offer a survival opportunity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。